pyridoxal phosphate has been researched along with Cardiovascular Diseases in 20 studies
Pyridoxal Phosphate: This is the active form of VITAMIN B 6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into pyridoxamine phosphate (PYRIDOXAMINE).
pyridoxal 5'-phosphate : The monophosphate ester obtained by condensation of phosphoric acid with the primary hydroxy group of pyridoxal.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Despite association found between PLP deficiency and low antioxidant status in critically ill patients, PLP deficiency was only associated with hyperhomocysteinemia regardless of antioxidant, riboflavin, cobalamine, and folate statuses in critically ill patients with SIRS at seventh day of ICU stay." | 7.83 | Pyridoxal-5'-phosphate deficiency is associated with hyperhomocysteinemia regardless of antioxidant, thiamine, riboflavin, cobalamine, and folate status in critically ill patients. ( de la Cruz, AP; Del Pozo, EP; Florea, D; Molina-López, J; Quintero-Osso, B; Rodríguez-Elvira, M, 2016) |
| "The purpose of this study was to determine if nonsupplementing older women (aged >or=55 years) with rheumatoid arthritis had higher plasma homocysteine and lower B-vitamin status compared to healthy controls." | 7.74 | Elevated plasma homocysteine and low vitamin B-6 status in nonsupplementing older women with rheumatoid arthritis. ( Manore, MM; Woolf, K, 2008) |
| "We studied predictors of homocysteine levels and correlations between homocysteine and (micro-)albuminuria, retinopathy, and history of cardiovascular disease in normotensive NIDDM subjects under stable metabolic control." | 7.70 | Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. ( Odekerken, DA; Rakic, M; Sijbrands, EJ; Silberbusch, J; Slaats, EH; Smulders, YM; Stehouwer, CD; Treskes, M, 1999) |
| " Despite association found between PLP deficiency and low antioxidant status in critically ill patients, PLP deficiency was only associated with hyperhomocysteinemia regardless of antioxidant, riboflavin, cobalamine, and folate statuses in critically ill patients with SIRS at seventh day of ICU stay." | 3.83 | Pyridoxal-5'-phosphate deficiency is associated with hyperhomocysteinemia regardless of antioxidant, thiamine, riboflavin, cobalamine, and folate status in critically ill patients. ( de la Cruz, AP; Del Pozo, EP; Florea, D; Molina-López, J; Quintero-Osso, B; Rodríguez-Elvira, M, 2016) |
| "The purpose of this study was to determine if nonsupplementing older women (aged >or=55 years) with rheumatoid arthritis had higher plasma homocysteine and lower B-vitamin status compared to healthy controls." | 3.74 | Elevated plasma homocysteine and low vitamin B-6 status in nonsupplementing older women with rheumatoid arthritis. ( Manore, MM; Woolf, K, 2008) |
| "We studied predictors of homocysteine levels and correlations between homocysteine and (micro-)albuminuria, retinopathy, and history of cardiovascular disease in normotensive NIDDM subjects under stable metabolic control." | 3.70 | Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. ( Odekerken, DA; Rakic, M; Sijbrands, EJ; Silberbusch, J; Slaats, EH; Smulders, YM; Stehouwer, CD; Treskes, M, 1999) |
| "The prevalence of hyperhomocysteinemia (tHcy > 12 micromol/L) was 56%, and 47% had low plasma folate levels (<3 ng/mL)." | 3.70 | Determinants of plasma total homocysteine levels in Korean chronic renal transplant recipients. ( Bang, BK; Bostom, AG; Dwyer, JT; Han, H; Jacques, PF; Kim, YS; Park, JH; Selhub, J, 2000) |
| " Adverse events were reported for 23% of the patients; most were mild to moderate in intensity, did not require treatment, and were not drug related." | 2.69 | Safety and efficacy of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the U.S. multicenter phase III clinical trials (safety). ( Anderson, MW; Borello, JA; Bova, JG; Brown, JJ; Chezmar, JL; Dachman, AH; Federle, MP; Fenstermacher, M; Foster, GS; Francis, IR; Freeny, PC; Halford, HH; Harmon, B; Harms, SE; Johnson, CD; Kenney, PJ; Klippenstein, DL; Lee, JK; Mattrey, R; Mitchell, DG; Pelsang, RE; Rubin, DL; Saini, S; Semelka, RC; Turner, DA; Weinreb, JC, 2000) |
| "There was a strong dose-response relation of plasma PLP concentration with plasma CRP." | 1.36 | Association of vitamin B-6 status with inflammation, oxidative stress, and chronic inflammatory conditions: the Boston Puerto Rican Health Study. ( Lai, CQ; Mattei, J; Ordovas, JM; Shen, J; Tucker, KL, 2010) |
| "Patients with diabetic nephropathy are at elevated cardiovascular risk." | 1.32 | Clinical and nutritional correlates of C-reactive protein in type 2 diabetic nephropathy. ( Bostom, AG; Friedman, AN; Hunsicker, LG; Selhub, J, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.00) | 18.7374 |
| 1990's | 4 (20.00) | 18.2507 |
| 2000's | 10 (50.00) | 29.6817 |
| 2010's | 3 (15.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ulvik, A | 1 |
| Midttun, Ø | 1 |
| McCann, A | 1 |
| Meyer, K | 1 |
| Tell, G | 1 |
| Nygård, O | 1 |
| Ueland, PM | 1 |
| Minović, I | 1 |
| Kieneker, LM | 1 |
| Gansevoort, RT | 1 |
| Eggersdorfer, M | 1 |
| Touw, DJ | 1 |
| Voerman, AJ | 1 |
| Connelly, MA | 1 |
| Boer, RA | 1 |
| Hak, E | 1 |
| Bos, J | 1 |
| Dullaart, RPF | 1 |
| Kema, IP | 1 |
| Bakker, SJL | 1 |
| Molina-López, J | 1 |
| Florea, D | 1 |
| Quintero-Osso, B | 1 |
| de la Cruz, AP | 1 |
| Rodríguez-Elvira, M | 1 |
| Del Pozo, EP | 1 |
| Busch, M | 1 |
| Göbert, A | 1 |
| Franke, S | 1 |
| Ott, U | 1 |
| Gerth, J | 1 |
| Müller, A | 1 |
| Stein, G | 1 |
| Bitsch, R | 1 |
| Wolf, G | 1 |
| Shen, J | 1 |
| Lai, CQ | 1 |
| Mattei, J | 1 |
| Ordovas, JM | 1 |
| Tucker, KL | 1 |
| MAEDA, Y | 1 |
| Friedman, AN | 1 |
| Hunsicker, LG | 1 |
| Selhub, J | 2 |
| Bostom, AG | 2 |
| Verrier, ED | 1 |
| Tardif, JC | 3 |
| Carrier, M | 3 |
| Kandzari, DE | 2 |
| Emery, R | 3 |
| Cote, R | 1 |
| Heinonen, T | 1 |
| Zettler, M | 1 |
| Hasselblad, V | 2 |
| Guertin, MC | 2 |
| Harrington, RA | 2 |
| Woolf, K | 1 |
| Manore, MM | 1 |
| Mehta, RH | 1 |
| Alexander, JH | 1 |
| Ellis, SJ | 1 |
| Khalil, A | 1 |
| Harrington, R | 1 |
| Han, Q | 1 |
| Lenz, M | 1 |
| Tan, Y | 1 |
| Xu, M | 1 |
| Sun, X | 1 |
| Tan, X | 2 |
| Tang, L | 1 |
| Miljkovic, D | 1 |
| Hoffman, RM | 1 |
| Smulders, YM | 1 |
| Rakic, M | 1 |
| Slaats, EH | 1 |
| Treskes, M | 1 |
| Sijbrands, EJ | 1 |
| Odekerken, DA | 1 |
| Stehouwer, CD | 1 |
| Silberbusch, J | 1 |
| Federle, MP | 1 |
| Chezmar, JL | 1 |
| Rubin, DL | 1 |
| Weinreb, JC | 1 |
| Freeny, PC | 1 |
| Semelka, RC | 1 |
| Brown, JJ | 1 |
| Borello, JA | 1 |
| Lee, JK | 1 |
| Mattrey, R | 1 |
| Dachman, AH | 1 |
| Saini, S | 1 |
| Harmon, B | 1 |
| Fenstermacher, M | 1 |
| Pelsang, RE | 1 |
| Harms, SE | 1 |
| Mitchell, DG | 1 |
| Halford, HH | 1 |
| Anderson, MW | 1 |
| Johnson, CD | 1 |
| Francis, IR | 1 |
| Bova, JG | 1 |
| Kenney, PJ | 1 |
| Klippenstein, DL | 1 |
| Foster, GS | 1 |
| Turner, DA | 1 |
| Han, H | 1 |
| Dwyer, JT | 1 |
| Jacques, PF | 1 |
| Park, JH | 1 |
| Kim, YS | 1 |
| Bang, BK | 1 |
| McKay, DL | 1 |
| Perrone, G | 1 |
| Rasmussen, H | 1 |
| Dallal, G | 1 |
| Blumberg, JB | 1 |
| Schuitemaker, GE | 1 |
| van der Pol, GA | 1 |
| Aretz, CP | 1 |
| Dinant, GJ | 1 |
| Steegers-Theunissen, RP | 1 |
| Boers, GH | 1 |
| Steegers, EA | 1 |
| Trijbels, FJ | 1 |
| Thomas, CM | 1 |
| Eskes, TK | 1 |
| Pessah-Rasmussen, H | 1 |
| Jerntorp, P | 1 |
| Stavenow, L | 1 |
| Elmstähl, S | 1 |
| Hansen, F | 1 |
| Seidegärd, J | 1 |
| Galvard, H | 1 |
| Brattström, L | 1 |
| Hamfelt, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Boston Puerto Rican Health Study: Center for Population Health and Health Disparities[NCT01231958] | 1,650 participants (Actual) | Observational | 2004-06-30 | Completed | |||
| [NCT00021918] | 0 participants | Observational | 2001-04-30 | Completed | |||
| MEND-CABG II: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG Surgery[NCT00402506] | Phase 3 | 3,000 participants (Anticipated) | Interventional | 2006-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 trials available for pyridoxal phosphate and Cardiovascular Diseases
| Article | Year |
|---|---|
Tryptophan catabolites as metabolic markers of vitamin B-6 status evaluated in cohorts of healthy adults and cardiovascular patients.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cohort Studies; Cross-Sectional Studies; Female; Humans; | 2020 |
Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Area Under Curve; Canada; Cardiopulmonary Bypa | 2007 |
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft
Topics: Cardiovascular Diseases; Coronary Artery Bypass; Coronary Disease; Double-Blind Method; Humans; Myoc | 2008 |
Safety and efficacy of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the U.S. multicenter phase III clinical trials (safety).
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Contrast Media; Diagnosis, | 2000 |
Multivitamin/mineral supplementation improves plasma B-vitamin status and homocysteine concentration in healthy older adults consuming a folate-fortified diet.
Topics: Aged; Aged, 80 and over; Aging; Cardiovascular Diseases; Cerebrovascular Disorders; Dietary Suppleme | 2000 |
A placebo-controlled, double-blind, randomised trial of magnesium-pyridoxal-5'-phosphate-glutamate for hypercholesterolaemia and other clinical-chemical risk factors of cardiovascular disease in a primary care setting.
Topics: Adult; Aged; Apolipoproteins A; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Fema | 2001 |
Effects of sub-50 oral contraceptives on homocysteine metabolism: a preliminary study.
Topics: Adult; Cardiovascular Diseases; Causality; Contraceptives, Oral; Desogestrel; Fasting; Female; Homoc | 1992 |
13 other studies available for pyridoxal phosphate and Cardiovascular Diseases
| Article | Year |
|---|---|
Vitamin B6, Inflammation, and Cardiovascular Outcome in a Population-Based Cohort: The Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study.
Topics: Adult; Aged; C-Reactive Protein; Cardiovascular Diseases; Female; Glycoproteins; Heart Disease Risk | 2020 |
Pyridoxal-5'-phosphate deficiency is associated with hyperhomocysteinemia regardless of antioxidant, thiamine, riboflavin, cobalamine, and folate status in critically ill patients.
Topics: Adult; APACHE; Biomarkers; Cardiovascular Diseases; Critical Illness; Female; Homocysteine; Humans; | 2016 |
Vitamin B6 metabolism in chronic kidney disease--relation to transsulfuration, advanced glycation and cardiovascular disease.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Erythrocytes; Female; Glycation End Product | 2010 |
Association of vitamin B-6 status with inflammation, oxidative stress, and chronic inflammatory conditions: the Boston Puerto Rican Health Study.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Boston; C-Reactive Protein; Cardiovascular Diseases; Cross-Sectio | 2010 |
THE EFFECT OF PYRIDOXAL PHOSPHATE ON SGO-T ACTIVITY IN MYOCARDIAL INFARCTION.
Topics: Aspartate Aminotransferases; Blood; Cardiovascular Diseases; Dogs; Myocardial Infarction; Pyridoxal | 1965 |
Clinical and nutritional correlates of C-reactive protein in type 2 diabetic nephropathy.
Topics: Adult; Aged; Blood Pressure; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Cholester | 2004 |
Translational research: is there a future?
Topics: Administration, Oral; Cardiopulmonary Bypass; Cardiovascular Diseases; Coronary Artery Bypass; Creat | 2007 |
Elevated plasma homocysteine and low vitamin B-6 status in nonsupplementing older women with rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; C-Reactive Protein; Cardiovascular Diseases; Case-Control Studies; Cros | 2008 |
Protective effect of pyridoxal-5-phosphate (MC-1) on perioperative myocardial infarction is independent of aortic cross clamp time: results from the MEND-CABG trial.
Topics: Adult; Aged; Aged, 80 and over; Aorta; Cardiovascular Diseases; Constriction; Coronary Artery Bypass | 2008 |
High expression, purification, and properties of recombinant homocysteine alpha, gamma-lyase.
Topics: Animals; Carbon-Sulfur Lyases; Cardiovascular Diseases; Chromatography; Cloning, Molecular; Cysteine | 1998 |
Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease.
Topics: Administration, Oral; Adult; Aged; Albuminuria; Analysis of Variance; Blood Pressure; Cardiovascular | 1999 |
Determinants of plasma total homocysteine levels in Korean chronic renal transplant recipients.
Topics: Adult; Aged; Cardiovascular Diseases; Creatinine; Cross-Sectional Studies; Fasting; Female; Folic Ac | 2000 |
Eighty-year-old men without cardiovascular disease in the community of Malmö. Part II. Smoking characteristics and ultrasound findings, with special reference to glutathione transferase and pyridoxal-5-phosphate.
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; G | 1990 |